Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
National Institutes of Health Clinical Center (CC) Identifier:
First received: July 11, 2001
Last updated: March 14, 2012
Last verified: March 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2008
  Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Ryan QC, Headlee D, Sparreboom A, et al.: A phase I trial of an oral histone deacetylase inhibitor, MS-275, in advanced solid tumor and lymphoma patients. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-802, 2003.